Energenesis Biomedical CO.,LTD. (TPE:6657)
30.00
+0.15 (0.50%)
Nov 13, 2026, 1:30 PM CST
TPE:6657 Revenue
Energenesis Biomedical CO.,LTD. had revenue of 1.85M TWD in the quarter ending June 30, 2026, a decrease of -10.27%. This brings the company's total for the last twelve months to 7.64M, down -4.36% year-over-year. In the year 2025, Energenesis Biomedical CO.,LTD. had annual revenue of 7.67M, down -0.97%. That makes Energenesis Biomedical CO.,LTD. the 45,388th largest company in the world by revenue and 2,185th in Taiwan.
Revenue (ttm)
7.64M
Revenue Growth
-4.36%
P/S Ratio
345.19
Revenue / Employee
n/a
Employees
35
Market Cap
2.64B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.67M | -75.00K | -0.97% |
| Dec 31, 2024 | 7.75M | 591.00K | 8.26% |
| Dec 31, 2023 | 7.16M | -193.00K | -2.63% |
| Dec 31, 2022 | 7.35M | -138.00K | -1.84% |
| Dec 31, 2021 | 7.49M | 408.00K | 5.76% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Syngen Biotech | 2.05B |
| Chunghwa Chemical Synthesis & Biotech | 934.29M |
| Sagittarius Life Science | 467.69M |
| BioGend Therapeutics | 235.24M |
| Intech Biopharm | 54.34M |
| Formosa Pharmaceuticals | 51.67M |
| Shine-On BioMedical | 50.62M |
| GlycoNex Incorporation | 19.51M |